Malaria vaccine trial raises hope

Child given blood test Malaria is caused by a parasite

Related Stories

A malaria vaccine has shown promising results in a clinical trial in Africa.

Infants given the prototype vaccine had about half the risk of getting malaria compared with those who did not receive the jab, say researchers.

The vaccine, known as RTS,S, is one of two experimental malaria vaccines being tested around the world.

More than 15,000 children aged under 18 months took part in the year-long study, published in The New England Journal of Medicine .

The trial was conducted in seven African countries on two groups of children - newborns aged six-12 weeks - and babies aged five-17 months.

One year on, there were about half the number of cases of malaria in the older group of children given the vaccine, compared with those in a control group who received vaccines against other illnesses.

"These data bring us to the cusp of having the world's first malaria vaccine," said Andrew Witty, chief executive of the British pharmaceutical company, GSK, which developed the vaccine alongside the non-profit PATH Malaria Vaccine Initiative.


The international team involved dozens of scientists in Africa and also the United States and Europe.

Start Quote

These initial results show that RTS,S/AS01 reduces malaria by half in children aged 5-17 months during the 12 months after vaccination ”

End Quote Study authors

The researchers wrote in The New England Journal of Medicine: "These initial results show that RTS,S/AS01 reduces malaria by half in children aged five-17 months during the 12 months after vaccination and that it has the potential to have an important impact on the burden of malaria in young African children."

Results in the younger infants are still being assessed.

Global health experts say the vaccine is less effective than others against common infections like polio and measles, and it is not yet clear how much it will cost.

Tsiri Agbenyega, a principal investigator in the vaccine trials in Ghana, said: "We would have wished that we could wipe it out, but I think this is going to contribute to the control of malaria rather than wiping it out."

Each year, about 225 million people get malaria, with about 800,000 deaths, mainly in African children.

GlaxoSmithKline's Andrew Witty lauded the work as an "incredible scientific achievement"

The World Health Organization said on Monday that there had been remarkable recent progress to combat the disease, with a nearly 20% fall in the number of deaths worldwide in the past 10 years.

A preliminary trial of another potential vaccine recently revealed promising results.

The trial was designed to test safety, but researchers found that 45 children given the MSP3 vaccine had high levels of protection.

The results of the Burkina Faso trial were also published in The New England Journal of Medicine.

The RTS,S study was funded by GSK and the PATH Malaria Vaccine Initiative, assisted by a grant from the Bill and Melinda Gates Foundation.

More on This Story

Related Stories

The BBC is not responsible for the content of external Internet sites

More Health stories



  • Mukesh SinghNo remorse

    Delhi bus rapist says victim shouldn't have fought back

  • Aimen DeanI spied

    The founder member of al-Qaeda who worked for MI6

  • Before and after shotsPerfect body

    Just how reliable are 'before and after' photos?

  • Lotus 97T driven by Elio de AngelisBeen and gone

    A champion F1 designer and other notable losses

  • A poster of Boris Nemtsov at a rally in St Petersburg, Russia, 1 MarchWho killed Nemtsov?

    Theories abound over murder that shocked Moscow

Try our new site and tell us what you think. Learn more
Take me there

Copyright © 2015 BBC. The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.